Zoetis Inc. (ZTS)
Zoetis' Q1: Market Overreaction Or Justified Drop?
The market did not like Zoetis Inc. earnings despite strong growth and the evidence that Zoetis is becoming a better business. Buybacks continued throughout the quarter and Zoetis is a good example of how consistent buybacks can become significant over long periods. Despite competitive pressures, key franchises like Simparica and Apoquel continue to grow. This portrays one of the attractive characteristics of the animal health industry.
Zoetis: Solid Q1 Results And A Weaker Dollar Provide Support (Upgrade)
Zoetis shares have underperformed, losing 8% over the past year, but recent solid earnings and guidance suggest shares are nearer to fair value, shifting my stance from "sell" to "hold.". The company reported $1.48 EPS, beating estimates, with 9% organic growth despite foreign exchange headwinds; US dollar weakness should boost future results. Zoetis maintains a strong balance sheet, with $1.7 billion cash and $6.6 billion debt, supporting shareholder returns through buybacks and dividends.
Zoetis Inc. (ZTS) Q1 2025 Earnings Call Transcript
Zoetis Inc. (NYSE:ZTS ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Steve Frank - Vice President of Investor Relations Kristin Peck - Chief Executive Officer Wetteny Joseph - Chief Financial Officer Conference Call Participants Erin Wright - Morgan Stanley Michael Ryskin - Bank of America Jon Block - Stifel David Westenberg - Piper Sandler Brandon Vazquez - William Blair Chris Schott - JPMorgan Navann Ty - BNP Paribas Daniel Clark - Leerink Partners Operator Welcome to the First Quarter 2025 Financial Results Conference Call and Webcast for Zoetis. Hosting the call today is Steve Frank, Vice President of Investor Relations for Zoetis.
Zoetis Q1 Earnings & Revenues Beat Estimates, '25 Outlook Raised
ZTS reports better-than-expected first-quarter results as earnings and revenues surpass estimates. Management raises 2025 guidance.
Compared to Estimates, Zoetis (ZTS) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Zoetis (ZTS) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zoetis (ZTS) Surpasses Q1 Earnings and Revenue Estimates
Zoetis (ZTS) came out with quarterly earnings of $1.48 per share, beating the Zacks Consensus Estimate of $1.40 per share. This compares to earnings of $1.38 per share a year ago.
Zoetis: Unleashing Margin Expansion; Initiate Strong Buy
We initiate coverage on Zoetis with a Strong Buy rating and a $219.26 price target, driven by explosive growth in companion animal products and structural margin expansion. Zoetis's leadership in companion animal therapeutics, particularly with Librela and Simparica, supports our above-consensus EPS forecasts of $6.12 for FY25 and $6.80 for FY26. The divestiture of lower-margin feed additives enables strategic R&D reinvestment, bolstering innovation and operational growth, while maintaining competitive moats in key markets.
Zoetis (ZTS) Q1 Earnings Preview: What You Should Know Beyond the Headline Estimates
Get a deeper insight into the potential performance of Zoetis (ZTS) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis Gears Up to Report Q1 Earnings: Here's What to Expect
ZTS' higher companion animal product sales are likely to have driven revenues in first-quarter 2025 in both the United States and International segments.
1 Superstar Dividend Growth Stock to Buy if the Market Crashes
The stock market has entered a new period of increased uncertainty and volatility following the Trump Administration's desire to reshape America's trade policies. While the market hasn't crashed outright, it has experienced multiple sessions of sharp losses, as well as dramatic rebounds.
Zoetis (ZTS) Advances But Underperforms Market: Key Facts
In the most recent trading session, Zoetis (ZTS) closed at $152.30, indicating a +0.92% shift from the previous trading day.
